ORION Holdings Subsidiary PAN ORION Acquires Convertible Preferred Shares in Ligachem Biosciences for 82.5 Billion KRW in Strategic Biotech Investment
ORION Holdings subsidiary PAN ORION Corp. Limited has decided to acquire 552,578 convertible preferred shares of Ligachem Biosciences for 82.5 billion KRW through a third-party allotment.
The investment aims to participate in a company selected for support from the Advanced Strategic Industry Fund, targeting growth in the biotech sector.
The convertible preferred shares are issued at 149,300 KRW per share, subject to a one-year lock-up, convertible into common shares from 2028, with the issuer holding a call option.
[AI Summary]ORION Holdings via its subsidiary invests 82.5 billion KRW in Ligachem Biosciences convertible preferred shares, expanding its biotech portfolio and securing future growth drivers. The investment represents about 5.5% of market cap, focusing on long-term value creation rather than short-term financial burden.
KOSPI Filing Information
Decision On Acquisition Of Stocks And Investment Securities Of Other Corporations (Voluntary Disclosure) (Major Management Matters Of Subsidiary)